WEIGHING IN: ACTUAL VS IDEAL VS ADJUSTED BODY WEIGTH TO CALCULATE DOSE OF MELPHALAN IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

被引：0
|
作者：
Kopp, Michelle [1 ]
Talamo, Giampaolo [1 ]
机构：
[1] Penn State Hershey Med Ctr, Hershey, PA USA
来源：
ONCOLOGY NURSING FORUM | 2015年 / 42卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
38
引用
收藏
页码：E155 / E155
页数：1
相关论文
共 50 条
  • [21] Bortezomib and Melphalan (Bor/MEL) Conditioning for Patients with Multiple Myeloma Undergoing Single Autologous Stem Cell Transplantation
    Zepeda, Victor H. Jimenez
    Duggan, Peter
    Neri, Paola E.
    Bahlis, Nizar J.
    BLOOD, 2014, 124 (21)
  • [22] Population Pharmacokinetics and Bayesian Estimation of Melphalan Concentrations in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
    Mizuno, K.
    Dong, M.
    Fukuda, T.
    Anaissie, E. J.
    Vinks, A. A.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 708 - 709
  • [23] Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight
    Waples, JM
    Moreb, JS
    Sugrue, M
    Belanger, G
    Kubilis, P
    Lynch, JW
    Gian, V
    Weeks, F
    Wingard, J
    BONE MARROW TRANSPLANTATION, 1999, 23 (09) : 867 - 873
  • [24] Busulfan and melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    Kim, Kihyun
    Choi, Yunsuk
    Eom, Hyeon-Seok
    Joo, Young Don
    Kim, Sung-Hyun
    Kwak, Jae-Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Lee, Ho Sup
    Mun, Yeung-Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Park, Seong Kyu
    Park, Yong
    Shin, Ho-Jin
    Yoon, Sung-Soo
    BONE MARROW TRANSPLANTATION, 2018, 53 : 262 - 263
  • [25] Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight
    JM Waples
    JS Moreb
    M Sugrue
    G Belanger
    P Kubilis
    JW Lynch
    V Gian
    F Weeks
    J Wingard
    Bone Marrow Transplantation, 1999, 23 : 867 - 873
  • [26] The efficacy of high-dose melphalan with autologous peripheral blood stem cell transplantation in patients with multiple myeloma
    Lee, JL
    Kim, SB
    Lee, GW
    Ryu, MH
    Kim, E
    Kim, S
    Kim, WK
    Lee, JS
    Kim, SH
    Suh, C
    YONSEI MEDICAL JOURNAL, 2003, 44 (05) : 800 - 810
  • [27] Autologous stem cell transplantation with high dose melphalan conditioning regimen is safe for elderly multiple myeloma patients
    Czyz, Anna
    Szeremet, Agnieszka
    Bogucka-Fedorczuk, Aleksandra
    Majcherek, Maciej
    Rybka, Justyna
    Prajs, Iwona
    Wrobel, Tomasz
    BONE MARROW TRANSPLANTATION, 2019, 54 : 499 - 500
  • [28] Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation
    Sharma, Atul
    Lokeshwar, Nilesh
    Raina, Vinod
    Mohanti, Bidhu K.
    Kumar, Rajive
    NATIONAL MEDICAL JOURNAL OF INDIA, 2007, 20 (03): : 121 - 124
  • [29] Intensive therapy with bortezomib and melphalan and autologous stem cell transplantation for patients with multiple myeloma
    Luo, Y.
    Tan, Y.
    He, J.
    Shi, J.
    Wu, W.
    Han, X.
    Zheng, G.
    Wei, G.
    Zheng, W.
    Ye, X.
    Cai, Z.
    Huang, H.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S264 - S264
  • [30] Effect of dose-adjusted melphalan on MRD-negativity to full dose melphalan in patients with multiple myeloma post-autologous stem cell transplant
    Kort, Jeries
    Ignatz-Hoover, James John
    Naleid, Nikolas
    Oley, Frank
    Cooper, Brenda W.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345